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Atomic resolution structures of cys-loop receptors, including one of a γ-aminobutyric
acid type A receptor (GABAA receptor) subtype, allow amazing insights into the
structural features and conformational changes that these pentameric ligand-gated
ion channels (pLGICs) display. Here we present a comprehensive analysis of more
than 30 cys-loop receptor structures of homologous proteins that revealed several
allosteric binding sites not previously described in GABAA receptors. These novel
binding sites were examined in GABAA receptor homology models and assessed as
putative candidate sites for allosteric ligands. Four so far undescribed putative ligand
binding sites were proposed for follow up studies based on their presence in the
GABAA receptor homology models. A comprehensive analysis of conserved structural
features in GABAA and glycine receptors (GlyRs), the glutamate gated ion channel,
the bacterial homologs Erwinia chrysanthemi (ELIC) and Gloeobacter violaceus GLIC,
and the serotonin type 3 (5-HT3) receptor was performed. The conserved features
were integrated into a master alignment that led to improved homology models. The
large fragment of the intracellular domain that is present in the structure of the 5-
HT3 receptor was utilized to generate GABAA receptor models with a corresponding
intracellular domain fragment. Results of mutational and photoaffinity ligand studies in
GABAA receptors were analyzed in the light of the model structures. This led to an
assignment of candidate ligands to two proposed novel pockets, candidate binding
sites for furosemide and neurosteroids in the trans-membrane domain were identified.
The homology models can serve as hypotheses generators, and some previously
controversial structural interpretations of biochemical data can be resolved in the
light of the presented multi-template approach to comparative modeling. Crystal and
cryo-EM microscopic structures of the closest homologs that were solved in different
conformational states provided important insights into structural rearrangements of
binding sites during conformational transitions. The impact of structural variation and
conformational motion on the shape of the investigated binding sites was analyzed.
Rules for best template and alignment choice were obtained and can generally be
applied to modeling of cys-loop receptors. Overall, we provide an updated structure
based view of ligand binding sites present in GABAA receptors.
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INTRODUCTION
γ-aminobutyric acid type A receptors (GABAA receptors)
are important drug targets in the treatment of various
neuropsychiatric conditions (Sieghart, 2015), and for the
induction and maintenance of general anesthesia (Olsen et al.,
2013; Antkowiak, 2015). Clinically used compounds such
as benzodiazepines, etomidate, propofol and others possess
allosteric binding sites and the binding to these sites changes
the response of the receptors to the agonist GABA. These
pentameric receptors are assembled in mammalian species as
homo- or heteropentamers from a repertoire of 19 subunits
(Sieghart, 1995; Olsen and Sieghart, 2008). This results in a
large variety of receptor subtypes (Olsen and Sieghart, 2008)
that display distinctive properties. Structurally seen, GABAA
receptors are typical members of the superfamily of pentameric
ligand-gated ion channels (pLGICs). Other members of this
superfamily, which are also known as cys-loop receptors, are the
nicotinic acetylcholine receptors (nAChRs), the serotonin type 3
receptors (5-HT3Rs) and the glycine receptors (GlyRs; Unwin,
2005; Du et al., 2015; Ernst and Sieghart, 2015; Huang et al.,
2015).
Most GABAA receptors are heteropentamers, whereby the
most abundant receptors’ subunit composition is α1, β2 and
γ2 subunits in the ratio 2:2:1 (Olsen and Sieghart, 2008). For
the interaction of drugs or other ligands with these receptors,
the interfaces between subunits play an important role as they
harbor binding sites. However, only few interfaces have been
studied extensively and confirmed to exist (Duncalfe et al., 1996;
Smith and Olsen, 2000; Chiara et al., 2012, 2013; Jayakar et al.,
2014). Receptors composed of α1, β3 and γ2 subunits were
shown to be arranged as β3−α1−γ2−β3−α1 (Tretter et al.,
1997, see ‘‘Supplementary Figure 1’’), and in experiments with
concatenated subunits the same arrangement was identified for
α1β2γ2 receptors (Baumann et al., 2001). The counter-clockwise
geometry (as viewed from extracellular) was determined later
with a homology model based on the X-ray structure of the
homologous acetylcholine binding protein (AChBP; Brejc et al.,
2001; Ernst et al., 2003). The existing interfaces in these subtypes
are thus β+/α1−, α1+/β−, α1+/γ2− and γ2+/β− (Tretter
et al., 1997; Baumann et al., 2001). It is assumed that in
αβγ subtypes with other α, β or γ isoforms the arrangement
is the same.
Receptors composed of four and even five different subunits
might also be formed, such as αβγ receptors containing
two different α or β subunits (Verdoorn, 1994; Olsen and
Sieghart, 2008). Examples for such subtypes are α1α3βγ receptors
(Ralvenius et al., 2015) or α1α5− containing receptors (Araujo
et al., 1999).
The arrangement of receptors that contain the δ subunit
together with α and β subunits (αβδ subtypes) is less clear
at this time (see ‘‘Supplementary Figure 1’’). Atomic force
microscopy identified in α4β3δ receptors the arrangement
β3−α4−δ−β3−α4 (Barrera et al., 2008; Eaton et al., 2014).
In this arrangement, δ is located in the same position as γ
in the αβγ subtypes. For other δ− containing receptors also
the arrangements β−α−δ−α−β or β−α−β−δ−α have been
proposed (Kaur et al., 2009; Sigel et al., 2009). Thus, the interfaces
α+/δ− or β+/δ−, as well as δ+/α− and δ+/β− could exist
in principle (see ‘‘Supplementary Figure 1’’). Lee et al. (2016)
have demonstrated the existence of a GABA site at the β+/δ−
interface.
The most prominent receptors comprising only two different
subunits are the αβ receptors in which the γ subunit is replaced
by a β subunit (Baumann et al., 2001; Mortensen and Smart,
2006). Here, the β+/β− interface exists as well (Tretter et al.,
1997; Baumann et al., 2001). Homopentameric GABAA receptors
can be formed of five ρ subunits. Other homopentamers and
thus homo-interfaces possibly exist as well. Two different ρ
subunits can assemble to form heteropentameric ρ receptors
(Olsen and Sieghart, 2008). Additional ρ− containing interfaces
may exist due to the identified co-assembly of ρ subunits
with the γ2 subunit (Qian and Pan, 2002). The composition,
stoichiometry and arrangement of receptors that contain the ε,
θ and pi subunits are so far unknown.
Of interest here are the localizations of ligand binding sites
on a prototypical GABAA receptor pentamer—independent of
the identity of the subunits that form it. Subtype differences can
then be studied in a next step, after binding site localization is
established. Binding site localizations based on indirect methods
and those based on atomic resolution structure determination are
briefly reviewed. Structural data has been selected based on the
presence of small molecule ligands in orthosteric and allosteric
binding sites, for more historical reviews of cys-loop receptor
structures see for example Lemoine et al. (2012), Nys et al. (2013),
daCosta and Baenziger (2013), Lynagh and Pless (2014) and
Sauguet et al. (2015).
Binding site localization of agonists and allosteric modulators
have long been established to exist at specific extracellular
interfaces, such as for the agonist GABA at the orthosteric
sites such as β+/α− interfaces (Smith and Olsen, 1994) as
well as allosteric sites for benzodiazepines at α+/γ− (Sigel and
Lüscher, 2011) and for pyrazoloquinolinones at α+/β− interfaces
(Sieghart et al., 2012). A Zn2+ site was proposed in the α+/β−
interface in a unique position that does not overlap with the
pyrazoloquinolinone site and is localized closer to the membrane
(Hosie et al., 2003). Many structures of cys-loop receptor family
members already exist with ligands bound to the extracellular
domain (ECD) interface (for example Hansen et al., 2005; Hibbs
and Gouaux, 2011; Pan et al., 2012a; Zimmermann et al., 2012;
Miller and Aricescu, 2014; Du et al., 2015; Huang et al., 2015;
Spurny et al., 2015) including a benzamidine bound crystal
structure of a β3− homopentameric GABAA receptor (Miller
and Aricescu, 2014). Interestingly, three (sub-) sites are observed
at the ECD-interface in the atomic structures (Pan et al., 2012a;
Spurny et al., 2012, 2015; Zimmermann et al., 2012; Miller and
Aricescu, 2014; Du et al., 2015; see Figure 1 and ‘‘Supplementary
Figure 2’’). The ECD-interface is largely formed by the so-called
loops A-C from the principal (plus) subunit and D-G of the
complementary (minus) subunit (Galzi and Changeux, 1994;
Sigel and Buhr, 1997; Ernst et al., 2003). Additionally, cation
binding sites have been observed in a localization closer to
the trans-membrane domain (TMD) and outside of the region
covered by loops A-G (Zimmermann et al., 2012).
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The interfaces between subunits of GABAA receptors also
have been shown to contain specific binding sites in the TMD
(TMD-interfaces). Highly efficient photoaffinity ligands allowed
recently to assign specific TMD-interfaces to etomidate (β+/α−,
Li et al., 2006; Chiara et al., 2012) and to barbiturate ligands
(α+/β− and γ+/β−, Chiara et al., 2013). More complex results
were obtained with photoreactive derivatives of propofol and
in mutational studies. These seem to indicate that propofol
sites exist in at least four different interfaces (Yip et al.,
2013; Jayakar et al., 2014; Lynagh and Laube, 2014; Franks,
2015; Stern and Forman, 2016) and possibly at additional
sites (Moraga-Cid et al., 2011). As was reported recently,
the α+/β− and γ+/β− containing interfaces in GABAA
receptors can also bind avermectin (Estrada-Mondragon and
Lynch, 2015), while the β+ containing interfaces cannot
accommodate this ligand. The action of many other ligands
has tentatively been connected with usage of these pockets as
well (Wingrove et al., 1994; Walters et al., 2000; McCracken
et al., 2010; Hanrahan et al., 2015; Luger et al., 2015;
Middendorp et al., 2015). While the X-ray crystallographic
structure of the β3− homopentameric GABAA receptor (Miller
and Aricescu, 2014) has no ligand bound at the TMD-interface,
structures of several related proteins were determined with
different ligands in positions consistent with the proposed
binding sites for etomidate, barbiturates, avermectin and other
ligands (for example Hibbs and Gouaux, 2011; Sauguet et al.,
2013; Althoff et al., 2014; Du et al., 2015). These ligand
bound structures, together with atomic structures in different
conformational states (Althoff et al., 2014; Sauguet et al.,
2014; Du et al., 2015), allow to investigate the structural
properties of the ligand binding sites localized at TMD-
interfaces.
The first allosteric binding site that was proposed to be
localized in GABAA receptors in a non-interface position is
a recently described site used by endocannabinoids such as
2-arachidonglycerol (2-AG) and anandamide (Sigel et al., 2011).
A crystal structure was found that contains a lipidmolecule in the
site that corresponds to the proposed 2-AG binding site (Bocquet
et al., 2009), which therefore allows structural studies for this site
in an occupied state.
A picrotoxinin binding site in the channel pore has
been known to exist in GABAA receptors, and was also
observed in crystal structures (Curtis et al., 1969; Hibbs
and Gouaux, 2011). Furthermore, additional ligands have
been observed to bind in the ion pore of homologous
proteins as well (Hilf et al., 2010; Spurny et al., 2013;
Chen et al., 2015). Multiple additional localizations were
observed for small molecule ligands in diverse structures
(for example Bocquet et al., 2009; Nury et al., 2011; Pan
et al., 2012a; Spurny et al., 2012, 2013, 2015; Zimmermann
et al., 2012; Sauguet et al., 2013). Here we investigate sites
that potentially can be targets of small molecule allosteric
modulators of GABAA receptor subtypes, revisit structural
insight on the known allosteric ECD-interface and TMD-
interface sites, and examine novel putative sites. All binding
sites that were studied in the selected experimentally
determined structures are summarized in Figure 1 and
FIGURE 1 | Ten small ligand binding sites are found in atomic
structures of γ -aminobutyric acid type A receptor (GABAA receptor)
homologs. The figure shows a side view of a superposition of the protein
data bank (PDB) files shown in boldface in Table 1. Representative ligand
positions were chosen for display of the 10 studied sites. Two subunits of
4COF are shown in ribbon representation (gray). The ligands are depicted in
space-filling representation, and the orginal PDB files are specified in Table 1.
More examples of ligands in these 10 site types are given in Table 1 and
“Supplementary Figure 2”.
Table 1. Channel blockers that bind to the ion pore are not
within the scope of this study which focuses on allosteric
modulatory sites.
In several of the analyzed structures multiple ligands
are present in diverse combinations. Some structures were
determined successfully with agonist molecules in the ECD and
allosteric modulators bound in TMD-sites (such as 3RIF, see
Table 1). In the ECD-interface in one instance multiple copies
of a ligand were observed (Stornaiuolo et al., 2013), and another
structure features simultaneous occupation of two (sub-) sites
in the ECD-interface by different ligands (Spurny et al., 2015;
see Table 1). Multiple copies of ligands also have been observed
in the TMD-interface and intra-subunit regions (Sauguet et al.,
2013, see ‘‘Supplementary Figure 2’’).
For the binding site localizations 4, 5, 6, 8 and 9 (see
Figure 1) that have been observed in structures of the bacterial
homologs GLIC and ELIC or members of the nAChR family
it is unclear if they exist in GABAA receptors at all. We thus
addressed the question how binding sites from these homologous
proteins map onto the GABAA receptor crystal structure, and
onto homologymodels of other GABAA receptor subtypes. Based
on this mapping we evaluated the likelihood of their existence
and attempted to assign ligands whose binding sites on GABAA
Frontiers in Molecular Neuroscience | www.frontiersin.org 3 June 2016 | Volume 9 | Article 44
Puthenkalam et al. Ligand Pockets in GABAA Receptors
TABLE 1 | Crystal structures used as templates or for mapping of putative binding sites1.
Pocket PDB ID Protein Ligand Reference
Extracellular interface sites:
ECD-interface (1) 4COF GABAA β3 Benzamidine (1, cyan) Miller and Aricescu (2014)
ECD-interface (1) 3RIF GluCl Glutamate Hibbs and Gouaux (2011)
ECD-interface (1) 3JAD GlyR α1 Strychnine Du et al. (2015)
ECD-interface (1) 3JAE GlyR α1 Glycine Du et al. (2015)
ECD-interface (1) 5CFB GlyR α3 Strychnine Huang et al. (2015)
ECD-interface (1) 2BYR AChBP Methyllycaconitine Hansen et al. (2005)
ECD-interface (1) 2BYS AChBP Lobeline Hansen et al. (2005)
ECD-interface (1) 4BFQ AChBP VUF9432 Stornaiuolo et al. (2013)
ECD-interface (1) 5AFJ nAChR α7-AChBP Lobeline Spurny et al. (2015)
ECD-interface (1) 4A97 ELIC R-Zopiclone Spurny et al. (2012)
ECD-interface (1) 4A98 ELIC Br-flurazepam Spurny et al. (2012)
ECD-interface (2) 4F8H GLIC R-Ketamine (2, cyan) Pan et al. (2012a)
ECD-interface (2) 5AFJ nAChR α7-AChBP Fragment 1 Spurny et al. (2015)
ECD-interface (3) 2YN6 ELIC Ba2+ (3, blue) Zimmermann et al. (2012)
Extracellular sites not at interfaces:
ECD-vestibule (4) 2YOE ELIC Flurazepam (4, brown) Spurny et al. (2012)
ECD-vestibule (4) 2YN6 ELIC Ba2+ Zimmermann et al. (2012)
ECD-vestibule (4) 5AFM nAChR α7-AChBP Fragment 4 Spurny et al. (2015)
ECD-helix 1 (6) 5AFJ nAChR α7-AChBP Fragment 1 (6, yellow) Spurny et al. (2015)
ECD-core (5) 3ZKR ELIC Br-(omoform) (5, magenta) Spurny et al. (2013)
Trans-membrane interface sites:
TMD-interface (7) 4HFD GLIC (F14’A Bromoform Sauguet et al. (2013)
TMD-interface (7) 4HFC GLIC (F14’A) Br-ethanol (7, orange) Sauguet et al. (2013)
TMD-interface (7) 4HFE GLIC (F14’A) Ethanol Sauguet et al. (2013)
TMD-interface (7) 3RIF GluCl Avermectin Hibbs and Gouaux (2011)
TMD-interface (7) 3RI5 GluCl Avermectin Hibbs and Gouaux (2011)
TMD-interface (7) 3RIA GluCl Avermectin Hibbs and Gouaux (2011)
TMD-interface (7) 3RHW GluCl Avermectin Hibbs and Gouaux (2011)
TMD-interface (7) 4TNW GluCl POPC Althoff et al. (2014)
TMD-interface (7) 3JAF GlyR α1 Avermectin Du et al. (2015)
Trans-membrane sites not at interfaces:
TMD intra-subunit (8) 3P4W GLIC Desflurane (8, green) Nury et al. (2011)
TMD intra-subunit (8) 3P50 GLIC Propofol Nury et al. (2011)
TMD intra-subunit (8) 4HFD GLIC (F14’A) Bromoform Sauguet et al. (2013)
TMD intra-subunit (8) 4HFH GLIC Bromoform Sauguet et al. (2013)
TMD M1/M4 (9) 3ZKR ELIC Br-(omoform; 9, red) Spurny et al. (2013)
TMD M3/M4 (10) 3EAM GLIC Lipid (10, dark green) Bocquet et al. (2009)
Additional structures:
4PIR 5-HT3A Hassaine et al. (2014)
4TNV GluCl Althoff et al. (2014)
2QC1 nAChR Dellisanti et al. (2007)
1Several PDB identifiers are listed multiple times because they contain more than one ligand, in different sites. Some structures contain additional ligands that are not
listed in the table, the reader is referred to the original PDB records for complete lists of ligands.
receptors have not yet been localized to any of these novel
pockets.
Furthermore, since only the structure of a single
conformation is available of an engineered GABAA receptor
(Miller and Aricescu, 2014) neither conformational variability
nor structural variability within the family can be studied at this
time on the basis of this crystal structure. However, structures
of the GlyR, the glutamate gated ion channel (GluCl) and GLIC
in different conformations exist. These reveal conformational
changes that happen in response to different events, such as
binding of ligands to different binding sites (Althoff et al.,
2014; Sauguet et al., 2014; Du et al., 2015). Thus, we employed
multiple structures (Hibbs and Gouaux, 2011; Althoff et al.,
2014; Du et al., 2015; Huang et al., 2015) in addition to the
GABAA receptor crystal structure (Miller and Aricescu, 2014)
as templates to gain more insight into the impact of protein
motion on pocket structures (see Table 1). We also studied
the recently solved structure of the 5-HT3 receptor with a
large intact intracellular domain (ICD) fragment (Hassaine
et al., 2014) to examine the putative ICD structure in GABAA
receptors.
MATERIALS AND METHODS
Template Selection
Apo- and ligand-bound structures of wild-type and mutant
homologous proteins of the GABAA receptors were
extracted from the protein data bank (PDB)1. The analyzed
1http://www.rcsb.org/pdb/
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structures are under the following accession numbers: AChBP
(2BYR, 2BYS), ELIC (2YOE, 3ZKR, 2YN6, 4A97, 4A98), GLIC
(3EAM, 3P4W, 3P50, 4F8H, 4HFH, 4HFE, 4HFD, 4HFC), GluCl
(3RIF, 3RHW, 3RI5, 3RIA, 4TNV, 4TNW), 5-HT3A (4PIR),
nAChR α7-AChBP-chimera (5AFJ, 5AFM), GlyR α1 (3JAD,
3JAE, 3JAF), GlyR α3 (5CFB) and the homopentameric GABAA
receptor β3 (4COF) which is the only available GABAA receptor
so far. All structures had sufficient resolution and quality for this
work, in which mainly protein backbone structure impacted on
the results.
Alignment Generation
Different crystal structures were analyzed for conserved elements
at the PDBeFold webserver2 which is a tool that generates
structural alignments based on secondary structure matching
(SSM, Krissinel and Henrick, 2004).
GABAA receptor sequences from the rat were obtained from
the UniProt database3. The signal peptides of the sequences
were removed, the sequences were trimmed at the N-terminal
end and the ICD was replaced by a short linker (e.g., AGT for
GluCl and GlyR based models and SQPARAA for 4COF based
models). (Multi) sequence alignments of the GABAA receptor
sequences and the homologous proteins were generated with
the ClustalX program4 (Thompson et al., 1994). PROMALS3D
was used for the sequence-to-structure alignments (Pei et al.,
2008). The results obtained in the 3D alignments were used
to manually correct alignments obtained with ClustalX and
PROMALS3D, see Figure 2 and ‘‘Supplementary Figure 3’’. A
master alignment for models based on 4COF as well as GlyR
and GluCl structures is provided in ‘‘Supplementary Table 3A’’,
a PROMALS3D derived alignment of selected GABAA receptor
subunits with the 4PIR structure is provided in ‘‘Supplementary
Table 3B’’.
Model Generation
The software MODELLER 9.95 was used to generate homology
models of the GABAA receptors by using the satisfaction
of spatial restraints method (Sali and Blundell, 1993). The
needed inputs for MODELLER are: one or more PDB-
file of the homologous template protein(s), an alignment of
the template(s) and the (optionally) trimmed rat GABAA
receptor sequences, and a python script to run the process.
Validation of the generated homology models was performed
with the PROCHECK program and the protein geometry tool in
MOE (Ramachandran-Plots, G-factor). Models based on 4COF
as well as the GlyR and GluCl structures were conventional
single template models based on the alignment shown in
‘‘Supplementary Figure 3A’’. The model with an ICD fragment
based on 4COF and 4PIR was based on 4COF for the ECD
and the TMD, and on 4PIR in the ICD. The transition between
the two templates was performed at the conserved M3 and
M4 residues that are depicted in Figure 3. ‘‘Supplementary
2http://www.ebi.ac.uk/msd-srv/ssm/
3http://www.uniprot.org/
4http://www.clustal.org/
5http://salilab.org/modeller/
Figure 3’’ includes details and the alignment variant used for the
Supplementary Model.
Pocket Mapping
Structures of GLIC, ELIC, AChBP and the nAChR-AChBP
chimera were superposed with 4COF at the PDBeFold
webserver6 based on secondary structure matching (SSM,
Krissinel and Henrick, 2004). Subsequently, the region around
the ligands that were co-crystallized in different structures
of GLIC, ELIC, AChBP and the nAChR-AChBP chimera
respectively was mapped according to the SSM superposition
as indicated in the alignments shown in ‘‘Supplementary
Figures 3C–E’’ and processed as indicated in ‘‘Supplementary
Figure 3’’ (workflow diagram). Pocket forming amino acids
that were identified as putatively conserved among the parent
structure and the GABAA receptors were then highlighted in
‘‘Supplementary Figure 3A’’.
Analysis of Conformational Changes
To assess global changes to individual domains, subunits and
at interfaces, RMSDs among α-carbon groups of appropriate
superpositions were employed. Thus, whole single subunits and
whole pentamers were superposed with the secondary structure
matching algorithm (Krissinel and Henrick, 2004), and with
a minimum RMSD calculator for subunit domains. Distances
between α-carbons of pocket forming residues were measured
and compared between the different models to study differences
in pocket structures.
RESULTS
GABAA Receptor Homology Models Based
on 4COF and Additional Templates
For many homology modeling studies concerned with GABAA
receptor subtypes, the obvious and best template will be the
β3 GABAA receptor structure (PDB ID 4COF, an engineered
human β3 homopentamer lacking the ICD) itself. A source of
uncertainty in 4COF based models comes from the variable
sequence length among GABAA receptor subunits, such as the
longer F loop region in α subunits compared to β3, or the longer
C loop of the ρ subunits (‘‘Supplementary Figure 3A’’). Thus,
if the 4COF structure is used as template for other GABAA
receptor subunits, such as the α, γ or δ subunits, stretches
of sequence with different length lead to so-called ‘‘INDELs’’
(concatenation of INsertion and DELetion, an alignment stretch
in which sequence length differs and thus leads to insertion
or deletion of amino acids relative to the aligned protein).
In turn, alignment algorithms (Thompson et al., 1994; Shi
et al., 2001; Pei et al., 2008) generate controversial solutions—a
phenomenon known as the ‘‘alignment problem’’ in homology
modeling.
Additional templates can be used to gain more insights
into conserved structural elements that are not detectable by
sequence alignment tools and thus resolve ambiguous alignments
6http://www.ebi.ac.uk/msd-srv/ssm/
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in variable regions. Use of additional structures has already
been applied elegantly in the past to better align target
sequences with the GluCl structure (Bergmann et al., 2013).
This approach was also employed here, and all presented models
are based on the alignment that results from combining 3D
superposition information from multiple structures (Krissinel
and Henrick, 2004) with sequence-to-structure tools (Pei et al.,
2008; see ‘‘Materials and Methods’’ Section and ‘‘Supplementary
Figure 3A’’). The superposition of multiple structures using
secondary structure matching as implemented in the PDBeFold
web service (Krissinel and Henrick, 2004) successfully aligns
structurally conserved amino acid residues even in the absence
of sequence similarity (see Figure 2). This restricts the possible
placement of INDELs considerably. If multiple 3D structures
are superposed, a conserved motif (for example VTG in
the β3 subunit) that forms a short strand 8′ emerges (see
Figure 2 and the alignment in ‘‘Supplementary Figure 3A’’)
with the hydrophobic// × (any amino acid)// hydrophobic (or
small)// pattern. Of this motif, the first hydrophobic position
is conserved even in the GLIC and ELIC proteins, indicating
an important structural role. Models based on alignments
in which polar side chains are placed into this position are
likely to be wrong as this hydrophobic residue seems to be
important for the structural integrity (hydrophobic packing).
If an alignment of a hydrophobic amino acid of, for example,
GABAA receptor α subunits with β3V175 is enforced, the
number of possible alignment variants of the F loop regions is
reduced considerably.
Once the master alignment has been established, it was
employed to generate models using the MODELLER program
(Sali and Blundell, 1993) based on several template structures.
Sequence similarity is often used as criterion for template
selection. The more stringent criterion of structural overlap
can be employed if structures are available that allow to
quantify structural similarity between remote family members.
Thus, the structural overlap was assessed between the GABAA
receptor and structures of the GlyR, GluCl, GLIC, ELIC, the
5-HT3R and members of the AChBP/nAChR family. Homology
models were subsequently built only on the basis of 4COF
and the eukaryotic homologs (GlyR, GluCl and the 5-HT3R)
as described in the methods. Structures from GLIC, ELIC,
AChBP and nAChRs were used only for 3D superposition
based pocket mapping, i.e., the localization of putative novel
binding pockets for small molecule ligands, while the pockets
were then studied in homology models based on the above
listed templates. To study the ICD, the 5-HT3R, that contains
a large fragment of the ICD (4PIR, Hassaine et al., 2014) was
employed in a multi-template approach together with 4COF,
see ‘‘Materials and Methods’’ Section. Due to the surprisingly
high structural and conformational similarity between the TMDs
of the 5-HT3R structure (4PIR) and the GABAA receptor
structure (4COF) and a very good overlap of the ICD-near
parts of M3 and M4 (see Figure 3) it was possible to
construct the two-templates models, see Figure 3. This structure
for the first time provides insight into the putative structure
of the N-terminal end of this important, highly variable and
regulatory domain.
FIGURE 2 | Conserved strand 8’ limits alignment choices in loop F
region. The structural overlay of a single subunits’ extracellular domain (ECD)
of all glycine receptor (GlyR) structures, all glutamate gated ion channel (GluCl)
structures and the GABAA receptor structure 4COF reveals a strict
conservation of the short strand 8’, which always starts with a hydrophobic
residue. The image shows the sequence alignment of the loop F region which
results from the 3D superposition, and the perfect overlay of the hydrophobic
residues in the indicated representative structures. Thus, for aligning
sequences of subunits with unknown structure to the resolved structures, the
hydrophobic position alignment that is emphasized by the magenta box must
be enforced. “Supplementary Figure 3A” (the master alignment) shows a
possible alignment of the 19 GABAA receptor subunits in this region to the
different structures to preserve strand 8’. Notably, Gloeobacter violaceus
(GLIC) and Erwinia chrysanthemi (ELIC) also feature this conserved motif (see
“Supplementary Figures 3D,E”).
The fragment C-terminal of M3 in the 5-HT3R consists of
a loop and a short α helix (termed MX), followed by missing
amino acids due to the proteolysis that was performed (Hassaine
et al., 2014). The C-terminal end of the ICD features the MA
helix that was also observed in the nAChR structure (Unwin,
2005). The question which of these elements may also be
present in GABAA receptor subunits can be answered only
tentatively on the basis of sequence alignments and sequence-to-
structure alignments that thread the GABAA receptor subunits’
sequences onto the 4PIR ICD structure and sequence. Basically,
no conserved motifs are detected near the putative MX region
by multi-sequence alignments. If single subunits or small multi-
sequence alignments such as the six α subunits are aligned to
the 4PIR structure using the PROMALS3D web service (Pei
et al., 2008), the connecting loop between M3 is predicted
to be as long as, or slightly shorter than the one seen in
the 4PIR structure (see ‘‘Supplementary Figure 3B’’). The MX
helix forming sequence aligns reasonably well with the GABAA
receptor β subunits, and less convincing with the α subunits.
For the γ subunits, no reasonable alignment can be obtained.
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FIGURE 3 | 3D superposition of 4PIR and 4COF and modeling of the GABAA receptor intact intracellular domain (ICD). (A) Superposition of 4PIR (cyan)
and 4COF (red) shows high structural similarity between the distant homologs. (B) Magnified view of the trans-membrane domain (TMD)-ICD interface. Strictly
conserved amino acids at the intracellular end of M3 and M4 superpose very well and are shown in stick representation, numbered according to 4COF (see also
“Supplementary Figure 3B”). (C) Side view of a homology model of the β3+/α1− interface (α1: yellow, β3: red) of the GABAA receptor with the ICD based on the
4PIR structure. α1F385 localizes to the α minus side of the interface in the model and has contacts with the β3+ pre-MX loop, and with the M1-M2 linker of α1. This
residue that has been implicated in propofol modulatory action thus likely localizes to the interface forming part of the ICD.
Thus, some GABAA receptor subunits may contain a similar
motif, while others may lack it—consistent with the diverse
functional roles of the ICD. The MA helix and the homologous
stretch of sequences in the GABAA receptor subunits also lack
any obvious conserved motif, so alignments are different and
remain ambiguous. However, for the C-terminal 20 amino acids
of the ICD until the beginning of M4 all sequence-to-structure
algorithms consistently align most GABAA receptor subunits
with the MA helix of 4PIR, strongly suggesting that MA is also
present in most GABAA receptor subunits (see ‘‘Supplementary
Figure 3B’’).
This is of particular interest because in a recent work it
was shown that α1F385 in the ICD has a major impact on
propofol’s ability to modulate GABAA receptors (Moraga-Cid
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et al., 2011). This raises the question if there might be an
additional propofol binding site in the ICD that accounts for
the modulatory effects of this ligand, and what the functional
role of the binding sites in the TMD might be that have been
observed by competition assays (Chiara et al., 2012, 2013) and
by photolabeling (Yip et al., 2013; Jayakar et al., 2014). The
mutational analysis pointing at the crucial role for α1F385
(Moraga-Cid et al., 2011) could have identified a binding site
residue, or a non-local factor that is important to stabilize a
particular conformational state. Mutations at very distant sites
(specifically at the plus side of the etomidate/propofol site near
the extracellular end of the TMD) can also disrupt allosteric
modulation by propofol (Krasowski et al., 2001), which suggests
that α1F385 is needed for the transduction of a conformational
change, but is not necessarily part of a propofol binding site.
However, this interpretation offers no explanation for the lack
of effect the α1F385 mutation has on etomidate potentiation
(Moraga-Cid et al., 2011). An alternative, and rather speculative
interpretation would be that propofol binds silently in the
pockets used by etomidate and barbiturates, and exerts its
modulatory effect by binding in a pocket near α1F385. This
hypothesis would consolidate the competitive action (Li et al.,
2010; Chiara et al., 2012) and the photoincorporation of ortho-
propofol diazirine at position β3H267 (Yip et al., 2013) by the
assumption of a silent site in the TMD and a propofol specific
modulatory site near α1F385 (Moraga-Cid et al., 2011). In a
homology model built on the basis of the alignment suggested
by the PROMALS3D server (Pei et al., 2008; see ‘‘Supplementary
Figure 3B’’), this amino acid localizes near the M1-M2 linker of
the same subunit on the α1minus side, and near the pre-MX loop
of the neighboring subunit’s plus side at the β+/α− interface.
This position could be equally consistent with a binding site or
a transduction site. Interestingly, the plus face of the MA helix
has been photolabeled in the nAChR α subunit by azietomidate
(Chiara et al., 2009b) and by chlorpromazine (Chiara et al.,
2009a), see ‘‘Supplementary Figure 3F’’. Further experiments are
needed to clarify the functional role of this region in mediating
ligand effects, and homology models of the ICD in GABAA
receptor subunits can serve as useful tools to select candidate
residues for further mutational analysis.
Mapping and Assessment of Binding Sites
in Models of GABAA Receptors
ECD-Interface (Orthosteric Site and Homologous
Allosteric Sites), Subsites 1 and 2 and the Cation
Site 3
The sites at the ECD-interface have been known long before
the first X-ray crystallographic structures revealed their 3D
structures (Sieghart, 1995). Many ligands have been assigned
successfully to individual ECD-interface subtypes in the past
(Hosie et al., 2003; Sieghart, 2015). It has been generally assumed
that loops A-G form one binding site, which usually is occupied
by one ligand. However, evidence from crystal structures strongly
suggests the existence of three subsites at the ECD-interface
that can be occupied by small molecules and cations either
individually or together. Subsite 1 is formed by amino acid
residues from loops B and C of the principal subunit, and from
loops E and D from the complementary subunit as seen in the
ligand interactions in the 4COF structure (see Figure 4 and
‘‘Supplementary Figure 2B’’). In all structures that were analyzed
here, most ECD-interface ligands are found in subsite 1 (see
Figure 4), including the GlyR antagonist strychnine (Du et al.,
2015; Huang et al., 2015).
Subsite 2 is formed by parts of loop C and pre-B residues
(from strand 7) on the plus side, and by part of the loops G
and F on the minus side (see Figure 4). Larger ligands can
occupy a space enclosed by loops A, B and C of the principal
subunit together with G, D and E, sometimes even F from
the complementary subunit, and thus occupy both subsites
simultaneously. This is the case for the methyllycaconitine bound
AChBP structure (2BYR, Hansen et al., 2005, see Figure 4).
Furthermore, subsite 2 at the ECD-interface apparently can be
occupied by a small molecule either alone (ketamine bound
GLIC) or together with another molecule that occupies subsite 1
(lobeline plus fragment 1 in 5AFJ). Yet another variation on
multiple ligands at the ECD-interface has been reported for
the AChBP (Stornaiuolo et al., 2013, PDB ID 4BFQ), where
multiple copies of the same ligand are bound ‘‘behind’’ loop
C (Stornaiuolo et al., 2013). Whether multiple ligands can
occupy the ECD-interface at the same time in GABAA receptors
cannot be evaluated on the basis of X-ray crystallographic
structural data, as benzamidine occupies only subsite 1 with
a single molecule. However, the evidence from all templates
together with the homology models suggest that both subsites
should exist in GABAA receptors and may be used by small
ligands independently, or by larger ligands that should occupy
the whole volume. Thus, in computational docking studies it
might be important to consider which part of the interface
is likely to harbor the small molecule of interest, or if it
is possible that several subsites are occupied simultaneously.
These findings may offer a structural explanation for the
observation that additional ligands can bind with unchanged
affinity to receptors into which the photoaffinity ligand
flunitrazepam has been covalently incorporated (McKernan
et al., 1998).
Subsite 3 harbors a Ba2+ ion in the ELIC structure
(Zimmermann et al., 2012) where it displays inhibitory effects.
A homologous site was described earlier based on mutagenesis
data in GABAA receptors (Hosie et al., 2003) as a binding site
for zinc ions. The binding site was proposed to be located in
the α+/β− interface and the binding site forming residues were
α1E137, α1H127 (both on β strand 7) and β3E182 (on loop F).
The homologous amino acids to β3E182 in the other subunits
are uncertain due to the ambiguity of the F loop alignment (see
‘‘Supplementary Figure 3A’’). Specific interfaces generally can
harbor cation binding sites in this localization.
Extracellular Intrasubunit Sites 4–6
Three additional binding sites not localized at subunit interfaces
were observed in the ECDs of various structures (see Figure 1,
Table 1). An intra-subunit site (site 4) was found to be
occupied by flurazepam in ELIC (Spurny et al., 2012) with
an access path pointing towards the channel vestibule (see
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FIGURE 4 | Multiple ligand binding sites at the extracellular domain (ECD)- interface. Left panel, 5AFJ: two different ligands occupy subsites 1 and 2
simultaneously in the nicotinic acetylcholine receptor (nAChR)- Acetylcholine binding protein (AChBP) chimera structure 5AFJ. Middle panel, 4F8H: subsite 2 is used
by ketamine without a ligand in subsite 1 (which is a proton site in GLIC) in the GLIC structure 4F8H. Right panel, superposition: the color codes match the ligands
for each structure in the overlay. Larger ligands like methyllycaconitine can use both sites simultaneously. However, most ligands are observed in subsite 1, as shown
in this overlay of six structures that was generated with a secondary structure match superposition. Only fragment 1 in 5AFJ, ketamine in 4F8H and a part of the
methyllycaconitine molecule in 2BYR occupy the site 2. Approximately 20 structures with ligands in the ECD interface were screened, and no other instances of site
2 usage were found in this sample (data not shown).
‘‘Supplementary Figure 4’’). The same site was also found
in other ELIC structures, occupied with glycerol (Pan et al.,
2012b) and Ba2+ (Spurny et al., 2013), as well in GLIC
accommodating acetate (Fourati et al., 2015). Different ions also
can bind at this position (Sauguet et al., 2014b). Furthermore,
the same pocket was occupied by an allosteric modulator
in the nAChR α7-AChBP chimera (fragment 4: 4,5-dibromo-
N-(3-hydroxypropyl)-1H-pyrrole-2-carboxamide; Spurny et al.,
2015). As this site is observed in many crystal structures of three
different proteins (ELIC, GLIC, nAChR- α7-AChBP chimera),
and flurazepam exerts effects in GABAA receptors that are
consistent with the usage of distinct high and low affinity
binding sites (Baur et al., 2008), we wondered if such a site 4
may exist in GABAA receptors as well. The crystal structures
and sequence alignments of the anion selective eukaryotic
homologs (GluCl, GABAA receptors and GlyRs) reveal that a
variable piece between β strands 5 and 5’ is longer in these
receptors compared to the proteins in which such an intra-
subunit binding site was seen (ELIC, GLIC and the nAChR α7-
AChBP chimera; ‘‘Supplementary Figures 3A, 4’’). This insertion
completely occludes the space in which ligands are seen in
the homologous proteins (see ‘‘Supplementary Figure 4’’). Thus
this putative site was rejected and not investigated further
here.
For the remaining ECD intrasubunit sites 5 and 6 the
homology models are fully consistent with pockets in these
localizations in GABAA receptor subtypes. The novel ECD-
intra-subunit binding site 5 was observed to contain bromoform
(an analog of the volatile anesthetic chloroform) in ELIC (Spurny
et al., 2013). Very recently, the same site was shown to be
occupied with xenon in GLIC (Sauguet et al., 2016). Site 5 is
located in the packing core between the ECD inner and outer
sheets near the disulfide bridge (see Figure 1). Close inspection
of this region in GABAA receptor homology models that are
based on the GABAA receptor crystal structure 4COF (Miller
and Aricescu, 2014) suggests that indeed small hydrophobic
molecules could in principle find enough space to bind in this
region. The putative pocket forming amino acids are indicated
in the master alignment (‘‘Supplementary Figure 3A’’). At this
time, no evidence exists which allows assignment of any known
GABAA receptor ligands to this site.
In the nAChR α7-AChBP chimera yet another allosteric
binding site that is formed in part by the N-terminal α helix
(helix 1, see site 6 in Figure 1) was observed (Spurny et al.,
2015). The existence of site 6 was also confirmed experimentally
in the nAChR where its ligand was shown to act as an negative
allosteric modulator (Spurny et al., 2015). The amino acid
residues putatively forming site 6 in GABAA receptor subunits
are highlighted in the master alignment (‘‘Supplementary
Figure 3A’’) and indicate some potential subunit specificity.
Although so far no experimental evidence exists that points to
such a site in any GABAA receptor subtype, many ligands act
at so far unidentified sites (Sieghart, 2015) and site-directed
mutagenesis experiments can be designed on the basis of our
models in order to investigate further. This site would have
the advantage to be directly located in a single subunit—thus
selective ligands would act at a single subunit, rather than at
an interface. Their affinity and efficacy thus would not depend
on two pocket forming subunits, which would make ligands of
site 6 very versatile tool compounds. Ligands acting at this site
in the nAChR were shown to exert inhibitory effects (i.e., act
as negative allosteric modulators or noncompetitive antagonists,
Spurny et al., 2015). For many GABAA receptor subtypes no
(allosteric or orthosteric) selective antagonists exist, thus a new
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FIGURE 5 | (A) Top and side views of the TMD of a GABAA receptor model (α6 subunit red, other subunits light pink) superposed with a single subunit of the
bromoform bound GLIC F14’A 4HFD structure (green). The pocket volume in 4HFD is occupied by three bromoform molecules (dark cyan volume) in the GLIC
structure at an intra-subunit site mainly formed by M1 and M2. The homologous pocket volume near α6I228 can accommodate a furosemide molecule (gray
volume). The side view is rendered from the outside of the channel between M1 and M4. The viewing perspective is indicated in the left image with an arrow.
(B) Localization of amino acids implicated in neurosteroid action relative to sites 9 and 10. The left panel displays a superposition of a single subunit’s TMD of the
bromoform bound ELIC structure 3ZKR (gray) with a homology model of a GABAA receptor α1 subunit based on 4TNW (yellow). Only a single Br atom of the
bromoform has been identified in the crystal structure, it is localized in a groove-like pocket between M1 and M4 on the minus side of the TMD and displayed here as
a magenta space-filling atom. Among the binding site forming residues in GLIC is W220, the homologous residue in the GABAA receptor α1 subunit is Q241. The
right panel depicts amino acids implicated in actions of neurosteroids at or near β+/α− interfaces along the whole length of the TMD (Hosie et al., 2006;
Bracamontes et al., 2012; Chen et al., 2012).
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class of noncompetitive allosteric antagonists would be most
useful.
TMD Inter-Subunit and Intra-Subunit Sites Near the
Junction with the ECD
The 4COF structure has no ligand bound to the TMD,
while several crystal structures feature very diverse ligands
bound to different places in this domain (see Figure 1 and
Table 1). There is agreement that the GABAA receptors’
TMD-interfaces (site 7) harbor binding sites for ligands
(for example etomidate, barbiturates, avermectin), in part
with considerable specificity for certain interfaces (Chiara
et al., 2012, 2013; Jayakar et al., 2014; Middendorp et al.,
2015; Maldifassi et al., 2016). A zinc binding site in the
TMD involving β3H267 and β3E270 has also been reported
(Hosie et al., 2003).
However, so far it remained unclear if other binding sites
exist in GABAA receptors’ TMD. Some sites have been proposed
on the basis of combined mutational and modeling studies
(Sigel et al., 2011; Baur et al., 2013), or by integrating data
from mutational and photoaffinity studies into computational
docking approaches (Alvarez and Estrin, 2015). Here we
approach this question based on ligand bound structures of
homologous proteins. Sites for bromoform, xenon and other
ligands were found in an intra-subunit localization in the
TMD of GLIC (Nury et al., 2011; Sauguet et al., 2013, 2016;
see Figure 1 and ‘‘Supplementary Figure 2’’). Such an intra-
subunit site (site 8) has also been observed for halothane and
etomidate with a combined photolabeling/modeling approach
in nAChRs (Forman and Miller, 2011). No ligands have
been identified in GABAA receptors for any such site this
far. On the other hand, for many ligands the binding sites
are unknown, as is the case for the α6− selective negative
allosteric modulator furosemide. A selectivity determinant for
furosemide is the M1 amino acid α6I228 (Thompson et al.,
1999). Mapping of the pockets that exist in GLIC (Nury
et al., 2011; Sauguet et al., 2013) onto α6-subunit containing
homology models reveals that α6I228 is homologous with
an amino acid that participates in binding of bromoform
and of desflurane in GLIC (Nury et al., 2011; Sauguet
et al., 2013; see Figure 5A). Homology models reveal that
such a pocket in an α6 subunit would contain amino acid
residues from M1, M2, and M3 (see also ‘‘Supplementary
Figure 3A’’). To clarify if the pocket also exists and is
large enough to accommodate ligands in GABAA receptors,
we did not rely only on the homology with GLIC, but
investigated the site 8 region in several homology models.
In α6β3γ2 homology models based on 4COF, as well as
on 3JAE, 3JAD and 4TNW an intra-subunit pocket is
localized in this space which actually can accommodate the
furosemide molecule (see Figure 5A) and the position of the
hydrophobic α6I228 is in a localization which is consistent
with α6− selective action of ligands using this site (all
other subunits have a polar amino acid in the homologous
position).
It is worth noting that sites 7 and 8 are formed by overlapping
parts of the TMD helices, and amino acid sidechains can be
FIGURE 6 | Binding sites in GABAA receptor homology models based
on structural evidence from homologous proteins. The image shows a
homology model based on 4COF (ECD, TMD) and 4PIR (ICD) with one
representative ligand per representative site: benzamidine in site 1 and
ketamine in site 2 (cyan), Ba2+ in site 3 (dark blue), bromoform in site 5 (right
subunit, magenta), fragment 1 in site 6 (left subunit, yellow), avermectin in site
7 (orange), desflurane in site 8 (green), bromoform in site 9 (right subunit, red),
2-arachidonglycerol (2-AG) in site 10 (left subunit, dark green). Note that each
of the sites could occur in five subunits or at five interfaces, respectively, but
may display ligand specificity. Some sites may not exist in all subunits or at all
interfaces. Amino acids putatively forming these sites are color coded in the
alignment shown in “Supplementary Figure 3A”.
localized near access to both sites. Moreover, both sites are
occupied simultaneously in a bromoform bound GLIC structure
(see ‘‘Supplementary Figure 2’’ and Table 1). Mutational analysis
has pointed at involvement of the region near sites 7 and 8 in
the β1 subunit in the action of salicylidene salicylhydrazide (SCS)
which has been identified as a β1 selective negative allosteric
modulator. Amino acids T255 (T230 in M1 of mature protein)
and I308 (I283 in M3 of mature protein) have been shown to
be crucial for its β1 subtype selectivity (Thompson et al., 2004).
Oddly, they do not seem to be part of a single pocket, but
rather are approximately 15 Å apart and nearly on opposite
sides of the β1 subunits’ TMD (‘‘Supplementary Figure 5’’).
Thus, it seems unlikely in the light of the structural evidence
that these two selectivity determinants form a pocket together.
The M3 position is localized on the plus side of the trans-
membrane interface, very close to the etomidate pocket of
the homologous β2,3 subunits (Chiara et al., 2012). It has
been shown recently that binding sites containing this part
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of the β+ TMD can confer negative allosteric modulation
(Estrada-Mondragon and Lynch, 2015), thus it is conceivable
that an SCS binding site indeed is localized at the TMD β1+
interface. On the other hand, given the close proximity of the
M1 residue to the region in which we localized the putative
furosemide site in the α6 subunit, another possible interpretation
would be that an SCS site is in an intra-subunit localization, and
the access to this pocket is determined by the M3 residue. Yet
another possibility would be that both pockets are occupied and
together elicit the functional effects. All these hypotheses can
be tested experimentally on the basis of the structural models
presented here.
Lipid and Putative Steroid Sites in the TMD
In site 9, a localization between M1 and M4 of a single subunit
(see Figure 1), a molecule of bromoform was found to bind in
ELIC (Spurny et al., 2013). In the GluCl structure 3RHW the
homologous position is occupied by a lipid fragment (Hibbs and
Gouaux, 2011). We thus investigated whether a ligand binding
site could exist in the homologous position of any GABAA
receptor subtype. A ligplot analysis of the bromoform bound
structure together with homology models of GABAA receptor
subtypes containing an α1 subunit revealed that the ELIC
residue W220 that is engaged in hydrophobic interactions with
bromoform is homologous with α1Q241 (see Figure 5B). This
amino acid was identified in mutational studies to be essential
for the positive modulatory action of neurosteroids (Hosie et al.,
2006). It was later demonstrated that the region around α1Q241
can be transposed to the β or γ subunit and induces steroid
sensitivity in chimeric constructs (Bracamontes et al., 2012). An
additional amino acid that was implicated in the modulatory
action of neurosteroids is residue α1N407 on M4 (Hosie et al.,
2006). Previous localizations of these residues based on a cryo-
EM structure of the nAChR (Unwin, 2005; Hosie et al., 2006)
in homology models were interpreted to form an intrasubunit
pocket. In the homology models based on the GABAA receptor
structure (Miller and Aricescu, 2014) the amino acids of the α1
subunit (Q241 on M1 and N407 on M4) that govern positive
modulatory action of neurosteroids are positioned around site
9 which is a groove at the subunit’s minus side where in
the crystal structures bromoform and lipid binding are observed
(see Figure 5B), rather than forming an intrasubunit pocket
(see ‘‘Supplementary Figure 6’’). These results so far suggest that
neurosteroids may exert part of their complex actions on α1−
containing receptors by binding to a TMD-M1/M4 site of the α1
subunit that is in the localization of site 9 in the crystal structures
(see Figure 5, Table 1).
In β3 homopentamers, a photoreactive steroid labeled β3F301
(Chen et al., 2012), indicating that while potentiation appears
to be α dependent (Bracamontes et al., 2012), steroid binding
also occurs in β3 homopentamers. The β3F301 is homologous
with β2L301, which was shown to participate in the modulatory
effects of anandamide and 2-AG on the GABAA receptors
containing the β2 subunit (Sigel et al., 2011; Baur et al.,
2013). Mutational analysis and computational docking studies
indicated that 2-AG modulates GABAA receptors by binding
at a localization which here is called site 10 (Sigel et al., 2011;
Baur et al., 2013). The residues contributing to this binding
site are β2M294, β2L301 and β2V302 on M3; β2S429, β2F432,
β2F433 and β2V436 on M4 (see ‘‘Supplementary Figure 3A’’),
and the homologous position contains a lipid molecule in the
GLIC 3EAM structure (Bocquet et al., 2009). These observations
suggest that neurosteroids and endocannabinoids can have
common or partially overlapping binding sites on GABAA
receptors, and that neurosteroids can possibly bind to multiple
sites in the TMD—namely sites 9 in alpha subunits and 10 in beta
subunits.
The functional role of site 10 cannot be deduced based on
this data. However, multiple sites have been proposed previously
(Hosie et al., 2006) as different amino acids compared to those
that mediate modulatory effects, namely α1T236 (M1) and
β3Y284 (M3) seem to be implied in direct activation of GABAA
receptors by steroids (Hosie et al., 2006). In previous models
based on a cryo-EM structure of the nAChR (Unwin, 2005)
these amino acids were proposed to form a common pocket
at the TMD β+/α− interface (Hosie et al., 2006), however, in
models based on 4COF this is not the case (see Figure 5B and
‘‘Supplementary Figure 6’’).
It seems that the effects of inhibitory steroids are elicited
by a completely different mechanism (Seljeset et al., 2015).
Thus, the total number of steroid binding sites on individual
GABAA receptor subytpes is unclear at this time. Previously
it was suggested on the basis of computational docking that
an interface pocket localization between the β+ and the α−
surfaces near the ICD would form one of the elusive steroid
binding sites (Alvarez and Estrin, 2015). While such a binding
site localization is not directly supported by any experimental
structure, its possible existence cannot be rejected on the basis
of the lack of a structure with a ligand in such a position.
However, the structural evidence (Bocquet et al., 2009; Hibbs
and Gouaux, 2011; Ulens et al., 2014) together with the
data from mutational analysis (Bracamontes et al., 2012) and
photoaffinity work (Chen et al., 2012) renders sites 9 and 10
as promising candidate sites for modulatory effects (site 9),
and activating effects (site 10), but fails to identify the role
of α1T236 in activating effects and provides no clue on the
inhibitory effects. Thus further studies will be needed to clarify,
and the models presented here can aid in the design of future
studies.
Summary of Binding Sites Proposed to Exist in
GABAA Receptors
Figure 6 provides an overview of the localizations of the already
previously known (1, 3, 7, 10) and the putative new (2, 5, 6, 8, and
9) allosteric sites in a model of a GABAA receptor. The model is
based on 4COF in the ECD and TMD, and includes the fragment
of the ICD observed in the 4PIR structure, which is modeled
according to this structure. The binding sites weremapped to this
dual template model to visualize their localizations relative to the
three domains and the subunit interfaces. The pocket mapping
results (see ‘‘Supplementary Figure 3A’’) can be utilized to design
mutational studies for the investigation of sites 1, 2, 3, 5, 6, 7, 8, 9
and 10 in any subtype of the GABAA receptor.
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Impact of Conformational Changes on the
Structure of Binding Sites
In a next crucial step we investigated the impact of
conformational changes on the structures of the binding
sites. To study any binding site structure in more detail and to
perform computational docking or virtual screening experiments
using homology models, it is necessary to assess which of the
available structures are the most suitable templates, and to clarify
if several templates have to be considered in order to study the
consequences of protein motion on a site of interest. Flexible
regions or regions that undergo strong motions or adapt ligand
induced fit states may not be in the desired conformation in
the 4COF structure which likely represents an agonist bound
desensitized state (Miller and Aricescu, 2014).
Conformational Changes in the GlyR and the GluCl
In order to determine how the structure of individual sites
changes during conformational transitions between states, we
generated homology models from two series of structures that
represent diverse ligand bound and conformational states. Cryo-
EM strutures of the GlyR α1 subtype have been obtained bound
with glycine (an agonist, 3JAE), strychnine (an antagonist, 3JAD)
and a combination of glycine and avermectin (3JAF; Du et al.,
2015), and a crystal structure of the GlyR α3 subtype in complex
with strychnine (5CFB; Huang et al., 2015) is also available.
Together, these enable researchers to study conformational
changes and induced fit from agonist (glycine), antagonist
(strychnine) and TMD-interface ligand (avermectin) binding.
The second series that was utilized here to study the impact of
protein motion on the different pockets of interest comprises the
GluCl structures which additionally include an apo state (Hibbs
and Gouaux, 2011; Althoff et al., 2014), see Table 1.
Domains, Subunits and Pentamers Compared within
and across GluCl, Glycine Receptors and the GABAA
Receptor Structures: Local and Global Motion,
Conserved and Variable Structure Elements
Superposition of individual domains was analyzed to understand
how individual domains change during conformational
transitions, and to assess similarity between the three
analyzed families (GluCl, GlyR, GABAA receptor). The apo
(4TNV), the POPC bound (4TNW) and the avermectin
bound states (3RIF, 3RIA, 3RHW) possess nearly identical
ECD structures, and no ‘‘capping’’ or ‘‘uncapping’’ motion of
loop C of the subunit can be detected at all (see Figure 7A
and ‘‘Supplementary Figure 7B’’, see also the analysis of the
interfaces below). While the loop C tips of all GluCl structures
and of the GABAA receptor β3-subunit overlap very closely
(to less than 1 Å), the situation is slightly different for the
GlyR structures. Specifically, the ECDs of the strychnine
bound GlyR structures 3JAD and 5CFB overlay less tightly
with the glycine bound and glycine/avermectin bound
stuctures. These two structures do display a small loop C
uncapping by approximately 2 Å compared to the glycine
bound GlyR structure 3JAE (see ‘‘Supplementary Figure 7B’’).
Additionally, the two strychnine bound structures display
complex rearrangements of the entire ECD, including a shift
in the position of the N-terminal helix 1 (see ‘‘Supplementary
Figure 7B’’).
The very high degree of overall conformational rigidity of the
ECD across the investigated structures reflects in a total root
mean square deviation (RMSD) among the α-carbon atoms of
1 Å for the GluCl structures, and 1–1.2 Å for the GlyRs. The high
structural conservation among these three families reflects in an
ECD RMSD of only 1.5 Å for the ECD superposition of 4COF
(representing the GABAA receptor) compared with 3JAD, 3JAE,
3JAF (three of the GlyR structures) and with 3RIF, 4TNV and
4TNW (representative, structurally diverse GluCl structures, see
‘‘Supplementary Figure 7C’’).
If the TMDs are superposed, an even smaller overall RMSD
of 1.2 Å results (see ‘‘Supplementary Figure 7C’’). Thus, the
individual domains are conformationally remarkably rigid, and
highly conserved across the analyzed anion channels. This
observation justifies the use of the GlyR and to some degree also
the GluCl as alternative templates for modeling GABAA receptor
subunits to take advantage of a larger choice of ligand bound
states and conformations that exist for these proteins.
If the entire subunits are superposed, the overall RMSD
increases to 2.1 Å, reflecting mainly the motions of the
two domains with respect to each other (‘‘Supplementary
Figure 7B’’). The ECD and TMD tilt and rotate/twist in relation
to each other (Althoff et al., 2014) during conformational
changes. These pronounced motions of the ECD and the TMD
relative to one another become evident (see ‘‘Supplementary
Figure 7B’’) if domain superpositions are compared with
subunit superpositions. For the entire GluCl and GlyR
series, the two domains move nearly rigid-body like and
the domains themselves show almost unchanged structures
in the different states (see Figure 7A and ‘‘Supplementary
Figure 7’’) as discussed above, with only the junction region
at the domain interface being slightly distorted in the course
of a twisting and tilting motion of the two domains relative to
one another.
When the whole pentamer is viewed, the changes in the
individual subunit (different tilt and twist angles of the ECD
and TMD) add up with changes of subunit position in
the pentamer (rotational and tilting motions of the entire
subunit with respect to the longitudinal pore axis). Grouped
by structural similarity, the structures fall into two groups
comprising a mixture of the proteins, that feature similar
conformations within the group. Pentamer superposition results
in lower RMSD values between the GlyR structures 3JAE
and 3JAF, the GluCl structure 3RIF (as well as 3RHW, 3RIA
and 3RI5), and the GABAA receptor structure 4COF. These
superpose within the range of 1.6–2.0 Å pairwise RMSD,
see tabulated values in ‘‘Supplementary Figure 7A’’. If any
of the former are compared with the GlyR structures 3JAD
and 5CFB, or the GluCl structures 4TNV and 4TNW, the
RMSD is >3Å throughout (see ‘‘Supplementary Figure 7A’’).
Thus, the first group contains GlyR and GluCl structures
of similar conformations. The GlyR structures 3JAE and
3JAF are similar to the GluCl structures 3RIF, 3RIA and
3RHW. The GlyR structures 3JAD and 5CFB are, on the
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FIGURE 7 | Impact of protein motion on the ECD and TMD interface pockets. (A) ECD binding site forming segments in models based on the indicated six
structures. The left panel shows the very close structural overlap that results from a superposition of the ECDs of single chains. The plus side forming segments A, B
and C are shown from two different perspectives, the minus side is depicted once. The color codes match the PDB IDs. The right panel shows the distinctly interface
geometries in the pentameric structures. The 4COF based interface (gray) is compared with models based on agonist (3JAE) and antagonist (3JAD) bound GlyR
template structures (blue/ cyan/ gray), as well as with apo- (4TNV) and differently ligated GluCl structures (red/orange/brown). Every interface has a unique geometry
due to the near rigid-body like movements which the ECD and TMD perform relative to one another during conformational changes, see also “Supplementary
Figures 7, 8”. (B) The TMD interface in two different protein conformations contains different pocket forming residues. The left panel shows a superposition of 4COF
with a β3 homopentamer model based on 4TNW, only the TMD is displayed. Two complete TMDs are displayed in different hues of red-brown, the plus side subunit
is darker. Of the other three subunits, only M2 is displayed in gray for orientation relative to the pore. The four amino acids that were used to quantify differences of
interface geometry (see “Supplementary Figure 9”) are shown in stick rendering. The other two panels display 4COF and the 4TNW based model viewed individually
from the same perspective as in the superposition, but the far end of the TMD is clipped for more clarity. In the 4COF structure β3H267 is localized in a remote
position to the subunit interface. A similar position is also observed in models based on the GluCl structure 3RIF. The 4TNW based β+/β− interface features β3H267
on the minus side of the interface vis a vis from β3N265, consistent with both residues being part of a single TMD-interface pocket. The position of β3H267 relative
to the interface is strikingly different in the two protein conformations.
other hand, more similar to the GluCl structures 4TNV
and 4TNW than to the GlyR structures 3JAE or 3JAF. The
benzamidinde bound GABAA receptor structure 4COF is in
a conformation most similar, but not identical with 3JAF of
the GlyR series and also quite similar to the GluCl structure
3RIF. Thus, the conformational differences seen between 3JAE
and the other GlyR structures, as well as between 3RIF and
the other GluCl structures, can be extrapolated to GABAA
receptor subunits, where similar changes also potentially
occur.
Binding Sites at Subunit Interfaces in Different
Conformations
Next we examined how the differences in pentamer and
dimer geometry impact on the binding sites localized at ECD
and TMD interfaces. Both the tilt angles and the rotational
position with respect to the longitudinal plane through the
interface of pocket forming surfaces in neighboring subunits
are different in all templates we considered for this analysis
(see Figure 7, ‘‘Supplementary Figures 7–9’’). The twist and
tilt of the ECD relative to the TMD translates into a marked
change of the angle between the complementary subunits’
minus side and the principal subunits’ plus side that leads
to an apparent change of loop C position relative to the
minus side (see ‘‘Supplementary Figure 7’’). It is important
to note though that this is a consequence of a nearly rigid-
body motion of the entire ECD, and not an isolated motion
of loop C. In fact, a seemingly more ‘‘uncapped’’ loop C
can be as close to loop D as a seemingly ‘‘capped’’ one
(see ‘‘Supplementary Figures 7,8’’, especially the distances
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between the tip of loop C and loop D in 4COF and
4TNV).
To quantify differences in relative positioning of all binding
site forming segments, distances between α-carbons of pocket
forming amino acids were examined (see ‘‘Supplementary
Figures 8, 9’’). For the ECD-interface we evaluated 10
distances between the plus and minus subunits to obtain
insight into the different pocket geometries for 4COF, and
for models derived from all GlyR structures and from all
GluCl structures, respectively. Figure 7 depicts the various
ECD-interface geometries that result from using 4COF, 3RIF,
4TNV, 4TNW, 3JAD and 3JAE as templates. From the distances
tabulated in ‘‘Supplementary Figure 8’’ it can be appreciated
that each ECD-interface has a unique geometry. Interestingly,
the strychnine bound structures feature a narrow subsite 2 (as
determined by distances between loop A and loops G and F,
see ‘‘Supplementary Figure 8’’) together with a wide subsite 1
(as indicated by distances from loops B and C to loops D
and E, see ‘‘Supplementary Figure 8’’). In contrast, subsite 1
is much narrower in structures that harbor small ligands in
this site (see ‘‘Supplementary Figure 8’’). Models based on the
apo-GluCl structure 4TNV display a large separation between
loop B and E, but a small distance between the tip of loop
C and the minus side (see ‘‘Supplementary Figure 8’’). From
this we conclude that multiple templates should be considered
carefully for computational docking studies—and not be chosen
based on highest sequence identity. If antagonist bound states
are of interest, 3JAD and 5CFB will be the templates of choice.
Otherwise, for very small ligands the templates with the smallest
pockets 3JAE or 3JAF, or the intermediate 4COF will be
appropriate choices, while for larger ligands 4TNW and 4TNV
might yield better results.
In addition to the impact of protein motion, structural
variability (i.e., structural differences among the different
proteins) is also evident. Of the ECD binding site forming
regions, strand 9 on the plus (principal) side, the loop F
region on the minus (complementary) side, and the region
near site 6 display structural variability (see alignment
shown in ‘‘Supplementary Figure 3A, 7’’). While the loop
F region does contain a small structurally conserved motif
(see Figure 2), the overall structure is quite different
among the different proteins (Nys et al., 2013). Structural
prediction of loop F and thus of subsites 2 and 3 at
the ECD-interface, as well as of site 6, will contain
considerable intrinsic uncertainty. To account for this,
neither template analysis nor homology modeling alone are
sufficient and more sophisticate computational methods are
needed.
The selective use of distinct TMD-interfaces by various
ligands (Wingrove et al., 1994; Chiara et al., 2012; Luger
et al., 2015) also leads to intense interest in structural
studies and computational docking for these sites. While
so far only the β+/α−, α+/β− and γ+/β− interfaces have
been assigned to specific ligands, homologous interfaces with
putative pockets exist at each subunit interface. ρ receptors
have been reported to be inhibited/negatively modulated by a
number of ligands (Belelli et al., 1999; Thomet et al., 2000)
that are allosteric positive modulators in αβ, αβγ or αβδ
receptors (Mihic et al., 1997; Bormann, 2000; Kaur et al.,
2009). The putative trans-membrane interface pockets that
may be present in δ-containing receptors have not yet been
explored at all, the same holds for θ, ε or pi-containing
receptors for which the respective subunit arrangements are
unknown.
It has been observed and discussed before that protein
conformation in the TMD is very crucial for pocket
properties, and thus must be considered carefully for
docking studies (Franks, 2015). Based on the detailed
analysis of across-interface and within-subunit distances
(see ‘‘Supplementary Figure 9’’) of models based on
all GlyR structures and all GluCl structures, as well as
on the GABAA receptor and the 5HT3-R structure, we
identified vastly different pocket shapes (see Figure 7B and
‘‘Supplementary Figure 9’’). The differences between the
interface geometries displayed by the individual members
of the GlyR series and the GluCl series is much more
pronounced in TMD-interface site 7 than in the ECD.
Interestingly, the avermectin bound state and the POPC
bound state of GluCl display very different TMD-interface
geometries (see ‘‘Supplementary Figure 9’’). However, the
avermectin bound GlyR structures overlap very well with
the avermectin bound GluCl. Thus, the analysis of different
structures demonstrates that the binding sites localized in
the TMD-interface (site 7) undergo marked conformational
changes.
These conformational changes are so large that the pocket
forming amino acids differ among different states. Amino
acid β3H267 of the GABAA receptor β3 subunit is site of
photoincorporation of ortho-propofol diazirine (Yip et al.,
2013). It has been argued previously that there might be
multiple, conformation-dependent pockets associated with
β3H267 (Franks, 2015) to which ligands might bind in a use-
dependent fashion. This obviously raises the question which
template structure, and thus which pocket conformation to select
for homology modeling and subsequent computational docking
studies to probe ligand-bound structures. Notably, in homology
models based on the 4TNW structure, the β3H267 side chain
is part of the minus site of site 7, and in close proximity to
the β3N265 on the plus side of the interface. In these models,
both these residues clearly are part of a continuous pocket
at the interface (see Figure 7B). Previously, based on a more
limited collection of structures, β3H267 was assumed to not be
part of the site 7 (barbiturate pocket) at the α+/β− or β+/β−
TMD-interface (Yip et al., 2013). Since propofol was reported
to competitively inhibit photoincorporation of 3H-azietomidate
(Chiara et al., 2012) and 3H-R-mTFD-MPAB (Chiara et al.,
2013), it ought to bind at an overlapping site. Our analysis of
motion at the trans-membrane interface now reconciles these
observations by showing that in certain conformations the
photolabeled residue β3H267 is part of the pocket containing
the β− interface part (barbiturate-pocket), see Figure 7B. This
is in agreement with a recent mutational study where the same
conclusion was reached (Stern and Forman, 2016). Thus, for
computational docking studies multiple templates should be
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used to sample these different structures, unless it is clear
which crystal structure corresponds to the ligand bound state
of interest. Use of the avermectin bound 3RIF structure to
localize the binding site of valerenic acid in the GABAA receptor
α1β2γ2 subtype was reported recently (Luger et al., 2015). In
this study the pocket in the 4COF structure, although more
homologous, was found too small and a model based on
the avermectin bound structure 3RIF was able to accommodate
the ligand.
Intrasubunit Binding Sites in Different Conformations
In contrast, the pockets that are localized within a single
subunit do not display large structural changes due to the
fact the subunits’ ECD and TMD behave nearly rigid-body
like. Indeed, we find distances between pocket forming α-
carbons to vary minimally (less than 1 Å) in pockets 5, 9 and
10. The situation is different for pocket 6 which is formed
in part by the conserved helix 1, and in part by loops that
differ in structure between the GlyR and the GluCl. Thus,
due to the higher similarity between GABAA receptors and
GlyRs, the GluCl may not be a valid template to model pocket
6. The region around pocket 6 also responds to antagonist
binding, as evidenced by different helix 1 conformations in
the strychnine bound GlyR structures, see ‘‘Supplementary
Figure 7C’’. The single subunits also display motion induced
changes in the ECD-TMD junction where pocket 8 is localized.
While in models based on the structures 4COF (GABAA
receptor), 4TNW (GluCl POPC bound state) and 3JAD (GlyR,
strychnine antagonist bound with a closed conformation of the
TMD) we find α6I228 of the putative furosemide pocket to
be orientated consistently towards the intra-subunit space (see
‘‘Supplementary Figure 7C’’), the shape and size of pocket 8
differs as indicated by changes in α-carbon distances of up to 2 Å.
Careful template comparison and the use of multiple templates is
thus advisable for structural studies of all ligand binding sites in
cys-loop receptors.
DISCUSSION
Since so far only a single GABAA receptor subtypes’ crystal
structure is available, all insight about structural differences
between the subtypes, and all information on different
protein conformations rests on sequence data and homology
models. Here we took advantage of a large number of
structures from homologous ligand-gated ion channels to
identify putatively conserved structural motifs that should
be present in all GABAA receptor subtypes, to gain insight
into protein motion, and to examine the influence of all
these factors on known and putative ligand binding sites.
While the structures we employed vary in the experimental
method by which they were determined and in the nominal
resolution, the structural properties that were of interest for
this work depend largely on backbone conformation. Therefore,
structures with lower resolution can be compared directly
with structures of higher resolution for the present analysis.
This would be different for computational docking or virtual
screening studies, for which resolution must be sufficient to
provide reliable sidechain coordinates in the binding site of
interest.
The high structural similarity between the GABAA receptor
structures’ TMD (Miller and Aricescu, 2014) with the remotely
homologous 5-HT3 receptor (Hassaine et al., 2014) demonstrates
impressively that the structural conservation in the cys-loop
family is extraordinarily high. The enormous diversity which
furnishes each family member and every receptor subtype
with unique pharmacological and electrophysiological properties
thus stems from a few highly variable domains, such as the
extracellular loops C and F on the one hand, and from
subtle differences in structural details on the other hand. The
influence of the large and variable intracellular domain on
the pharmacological properties of receptor subtypes is largely
unclear at this time.
The high degree of overall structural conservation allowed
the use of multi-template modeling to integrate information
from several related proteins into GABAA receptor models. We
identified 10 distinct binding pockets for small molecules and
cations per subunit to exist in various atomic structures. Four
pockets (1, 2, 3 and 7) are located at interfaces, and are thus
formed by two subunits together. The remaining six pockets are
formed mostly or completely by a single subunit. Of these 10
small molecule binding pockets, four have been already described
before to exist in diverse GABAA receptor subunits and at
interfaces formed by specific neighboring subunits. Specifically,
sites at the extracellular interface (subsite 1, or subsites 1 and
2 together and the cation binding site 3) and at the TMD-
interface near the ECD have already been assigned to various
ligands (Sieghart, 2015). In addition, a site formed by parts of
the M3 and M4 helices close to the ICD of the β2 subunit has
been described as interaction site for the endocannabinoid signal
molecules such as anandamide and 2-AG (Sigel et al., 2011; Baur
et al., 2013).
By constructing homology models onmultiple structures, and
by mapping binding sites from more remote homologs (such as
GLIC and ELIC) onto the homology models based on 4COF,
the GlyR and the GluCl, we investigated also the novel sites
4, 5, 6 and 9. Of the sites that so far have not been described
in GABAA receptors, we determined that site 4 (localized at
the channel vestibule) which was observed in three homologous
proteins (Spurny et al., 2012, 2015; Fourati et al., 2015) does
not exist in GABAA or GlyRs. Site 5, a small hydrophobic space
within the packing core of the ECD near the disulfide bridge may
accommodate small hydrophobic molecules, but we were unable
to assign candidate ligands to this site as no experimental
evidence such as mutational studies point at the putative pocket
forming residues as mediating effects of any ligand. Of interest is
the putative existence of site 6, a cavity formed by the N-terminal
helix 1 and loop regions which has been described for the nAChR
α7−AChBP chimera and a nAChR. Ligands that bind to this site
in the nAChR act as negative modulators (Spurny et al., 2015).
In GABAA receptor subunits, the pocket forming amino acids
would differ strongly between certain subunits, and thus this
putative pocket would be suitable for subtype selective targeting
of selected subunits. Furthermore, ligands acting at this site
would be selective for a single subunit, as opposed to ligands
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that act at an interface-site which imparts selectivity towards
both pocket forming subunits. While no ligand assignment
was possible for any of the newly proposed pockets in the ECD,
for the TMD-intra-subunit site 8 we identified furosemide as a
strong candidate ligand for the α6 subunit’s site 8. Site 9 which
is formed by M1 and M4, likely together with the lipid bilayer,
is a candidate for the modulatory site of neurosteroids. This
site is very similar to the endocannabinoid site 10 (Baur et al.,
2013).
We found that protein motion has a large impact on the
pockets contained at subunit interfaces, but much smaller effects
on intra-subunit sites. Thus, templates which feature different
conformational states of the ECD such as the strychnine bound
glycine receptor structures (Du et al., 2015; Huang et al., 2015)
need to be considered if larger ligands or ligands that exert
antagonistic effects shall be docked into the homolgy models.
However, regions that are subject both to sequence variability
and conformational motion, such as loops C and F, or the
junction zone that connects the ECD and TMD, cannot be
modeled with high accuracy on any of the available structures
at this time and may in addition to sampling the templates
broadly require post-modeling procedures such as loop sampling
(Sali and Blundell, 1993) and experimental data guided model
ranking (Richter et al., 2012; Middendorp et al., 2014) prior to
performing advanced computational docking studies or virtual
screens.
Analysis of the same region of interest, such as site 7,
in different experimental structures has led to important
insights regarding the interpretation of sidechain positions
with respect to ‘‘pockets’’ or other protein surfaces. Not
only limited accuracy of low resolution structures, but
also pronounced difference in conformational states can
result in controversial sidechain localization. This was
exemplified for residues implicated in steroid action
(Hosie et al., 2009) as well as in binding sites used by
anesthetic compounds (Yip et al., 2013; Franks, 2015;
Stern and Forman, 2016). Studies in which structural data
is utilized should therefore never be restricted to ‘‘the
closest homolog’’, or ‘‘the highest resolution structure’’,
instead, the available breadth of information needs to
be integrated to arrive at reasonable estimates of possible
uncertainty.
We also presented the first models that incorporate a
large ICD fragment. Overall, the models presented here help
to localize amino acid residues that have been identified as
crucial for ligand effects by biochemical means (Thompson
et al., 1999, 2004; Hosie et al., 2006; Carland et al., 2009;
Chen et al., 2012; Baur et al., 2013; Estrada-Mondragon and
Lynch, 2015) and to explore their structural vicinity. This
leads to testable hypotheses regarding the role of specific
amino acids in ligand effects. In the interpretation of the
models and the putative pocket contributing segments
(see ‘‘Supplementary Figure 3A’’) the limitations inherent
to the method need to be kept in mind. The strictly
conserved parts of the backbone that can be deduced from
appropriate 3D superpositions will be the most reliable
parts of structural models, while more variable regions
and INDELS will be of limited reliability. Whether a
difference in amino acids between subtypes or species can
reliably be utilized for computational work such as docking
depends on its localization on conserved or variable parts.
Thus, comparing different structures thoroughly and in
detail is invaluable also to deal with the limits in model
accuracy.
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